Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felipe Martinez

Showing results (91-100 of 137) with videos related to

Pageof 14
Sort By:
Clinical Cardiology|July 29, 2016
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS TrialLarry R Jackson, Jonathan P Piccini, Derek D Cyr, et al.
Diagnostics (Basel, Switzerland)|April 26, 2024
Multi-Modality Imaging in VasculitisMohamed N Allam, Nima Baba Ali, Ahmed K Mahmoud, et al.
Hypertension (Dallas, Tex. : 1979)|July 26, 2006
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapyStevo Julius, Michael A Weber, Sverre E Kjeldsen, et al.
Journal of the American College of Cardiology|November 7, 2015
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HFJoanne Simpson, Pardeep S Jhund, Jose Silva Cardoso, et al.
JAMA Cardiology|October 3, 2022
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialMuthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
Circulation. Heart Failure|January 13, 2016
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure TrialSøren L Kristensen, David Preiss, Pardeep S Jhund, et al.
European Heart Journal|January 28, 2025
Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trialAlexander Peikert, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation|July 16, 2013
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrelMatthew T Roe, Shaun G Goodman, E Magnus Ohman, et al.
JACC. Heart Failure|September 16, 2022
Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionPeder L Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
European Journal of Heart Failure|August 26, 2023
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trialMaria Pabon, Brian L Claggett, Xiaowen Wang, et al.
Pageof 14

Showing results (91-100 of 137) with videos related to

Sort By:
Pageof 14
Clinical Cardiology|July 29, 2016
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS TrialLarry R Jackson, Jonathan P Piccini, Derek D Cyr, et al.
Diagnostics (Basel, Switzerland)|April 26, 2024
Multi-Modality Imaging in VasculitisMohamed N Allam, Nima Baba Ali, Ahmed K Mahmoud, et al.
Hypertension (Dallas, Tex. : 1979)|July 26, 2006
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapyStevo Julius, Michael A Weber, Sverre E Kjeldsen, et al.
Journal of the American College of Cardiology|November 7, 2015
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HFJoanne Simpson, Pardeep S Jhund, Jose Silva Cardoso, et al.
JAMA Cardiology|October 3, 2022
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialMuthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
Circulation. Heart Failure|January 13, 2016
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure TrialSøren L Kristensen, David Preiss, Pardeep S Jhund, et al.
European Heart Journal|January 28, 2025
Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trialAlexander Peikert, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation|July 16, 2013
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrelMatthew T Roe, Shaun G Goodman, E Magnus Ohman, et al.
JACC. Heart Failure|September 16, 2022
Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionPeder L Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
European Journal of Heart Failure|August 26, 2023
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trialMaria Pabon, Brian L Claggett, Xiaowen Wang, et al.
Pageof 14